Your browser doesn't support javascript.
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
1.
Clin Transl Med ; 12(9): e1025, 2022 09.
Article Dans Anglais | MEDLINE | ID: covidwho-2027333

Résumé

BACKGROUND: Patients with COVID-19 display a broad spectrum of manifestations from asymptomatic to life-threatening disease with dysregulated immune responses. Mechanisms underlying the detrimental immune responses and disease severity remain elusive. METHODS: We investigated a total of 137 APs infected with SARS-CoV-2. Patients were divided into mild and severe patient groups based on their requirement of oxygen supplementation. All blood samples from APs were collected within three weeks after symptom onset. Freshly isolated PBMCs were investigated for B cell subsets, their homing potential, activation state, mitochondrial functionality and proliferative response. Plasma samples were tested for cytokine concentration, and titer of Nabs, RBD-, S1-, SSA/Ro- and dsDNA-specific IgG. RESULTS: While critically ill patients displayed predominantly extrafollicular B cell activation with elevated inflammation, mild patients counteracted the disease through the timely induction of mitochondrial dysfunction in B cells within the first week post symptom onset. Rapidly increased mitochondrial dysfunction, which was caused by infection-induced excessive intracellular calcium accumulation, suppressed excessive extrafollicular responses, leading to increased neutralizing potency index and decreased inflammatory cytokine production. Patients who received prior COVID-19 vaccines before infection displayed significantly decreased extrafollicular B cell responses and mild disease. CONCLUSION: Our results reveal an immune mechanism that controls SARS-CoV-2-induced detrimental B cell responses and COVID-19 severity, which may have implications for viral pathogenesis, therapeutic interventions and vaccine development.


Sujets)
COVID-19 , Vaccins antiviraux , Lymphocytes B , Vaccins contre la COVID-19 , Cytokines , Humains , Mitochondries , SARS-CoV-2 , Indice de gravité de la maladie , Vaccins antiviraux/pharmacologie
2.
Front Immunol ; 12: 799896, 2021.
Article Dans Anglais | MEDLINE | ID: covidwho-1662583

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection results in rapid T lymphocytopenia and functional impairment of T cells. The underlying mechanism, however, remains incompletely understood. In this study, we focused on characterizing the phenotype and kinetics of T-cell subsets with mitochondrial dysfunction (MD) by multicolor flow cytometry and investigating the association between MD and T-cell functionality. While 73.9% of study subjects displayed clinical lymphocytopenia upon hospital admission, a significant reduction of CD4 or CD8 T-cell frequency was found in all asymptomatic, symptomatic, and convalescent cases. CD4 and CD8 T cells with increased MD were found in both asymptomatic and symptomatic patients within the first week of symptom onset. Lower proportion of memory CD8 T cell with MD was found in severe patients than in mild ones at the stage of disease progression. Critically, the frequency of T cells with MD in symptomatic patients was preferentially associated with CD4 T-cell loss and CD8 T-cell hyperactivation, respectively. Patients bearing effector memory CD4 and CD8 T cells with the phenotype of high MD exhibited poorer T-cell responses upon either phorbol 12-myristate-13-acetate (PMA)/ionomycin or SARS-CoV-2 peptide stimulation than those with low MD. Our findings demonstrated an MD-associated mechanism underlying SARS-CoV-2-induced T lymphocytopenia and functional impairment during the acute phase of infection.


Sujets)
COVID-19/complications , Lymphopénie/complications , Lymphopénie/étiologie , Maladies mitochondriales/étiologie , Adulte , Sujet âgé , Lymphocytes T CD4+/immunologie , Lymphocytes T CD8+/immunologie , COVID-19/immunologie , Femelle , Humains , Mémoire immunologique/immunologie , Ionomycine/usage thérapeutique , Lymphopénie/immunologie , Mâle , Adulte d'âge moyen , Mitochondries/immunologie , Maladies mitochondriales/immunologie , Phosphoryl-choline/analogues et dérivés , Phosphoryl-choline/usage thérapeutique , Poly(acides méthacryliques)/usage thérapeutique ,
3.
Sci Adv ; 6(35): eaba7910, 2020 08.
Article Dans Anglais | MEDLINE | ID: covidwho-760200

Résumé

Targeting a universal host protein exploited by most viruses would be a game-changing strategy that offers broad-spectrum solution and rapid pandemic control including the current COVID-19. Here, we found a common YxxØ-motif of multiple viruses that exploits host AP2M1 for intracellular trafficking. A library chemical, N-(p-amylcinnamoyl)anthranilic acid (ACA), was identified to interrupt AP2M1-virus interaction and exhibit potent antiviral efficacy against a number of viruses in vitro and in vivo, including the influenza A viruses (IAVs), Zika virus (ZIKV), human immunodeficiency virus, and coronaviruses including MERS-CoV and SARS-CoV-2. YxxØ mutation, AP2M1 depletion, or disruption by ACA causes incorrect localization of viral proteins, which is exemplified by the failure of nuclear import of IAV nucleoprotein and diminished endoplasmic reticulum localization of ZIKV-NS3 and enterovirus-A71-2C proteins, thereby suppressing viral replication. Our study reveals an evolutionarily conserved mechanism of protein-protein interaction between host and virus that can serve as a broad-spectrum antiviral target.


Sujets)
Protéines adaptatrices du transport vésiculaire/métabolisme , Antiviraux/pharmacologie , Cinnamates/pharmacologie , Infections à coronavirus/traitement médicamenteux , Infections à VIH/traitement médicamenteux , Grippe humaine/traitement médicamenteux , Pneumopathie virale/traitement médicamenteux , ortho-Aminobenzoates/pharmacologie , Cellules A549 , Animaux , Betacoronavirus/effets des médicaments et des substances chimiques , Sites de fixation/génétique , COVID-19 , Lignée cellulaire tumorale , Chlorocebus aethiops , Infections à coronavirus/anatomopathologie , Chiens , Cellules HEK293 , Infections à VIH/anatomopathologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/effets des médicaments et des substances chimiques , Interactions hôte-pathogène/effets des médicaments et des substances chimiques , Humains , Virus de la grippe A/effets des médicaments et des substances chimiques , Grippe humaine/anatomopathologie , Cellules rénales canines Madin-Darby , Souris , Souris de lignée BALB C , Souris de lignée C57BL , Souris knockout , Coronavirus du syndrome respiratoire du Moyen-Orient/effets des médicaments et des substances chimiques , Pandémies , Pneumopathie virale/anatomopathologie , Liaison aux protéines/génétique , Transport des protéines/effets des médicaments et des substances chimiques , ARN viral/génétique , Récepteur à l'interféron alpha-bêta/génétique , SARS-CoV-2 , Facteur de croissance transformant bêta-1/métabolisme , Cellules Vero , Réplication virale/effets des médicaments et des substances chimiques , Virus Zika/effets des médicaments et des substances chimiques , Infection par le virus Zika/anatomopathologie
4.
Immunity ; 53(4): 864-877.e5, 2020 10 13.
Article Dans Anglais | MEDLINE | ID: covidwho-693493

Résumé

The SARS-CoV-2 pandemic has resulted in millions of infections, yet the role of host immune responses in early COVID-19 pathogenesis remains unclear. By investigating 17 acute and 24 convalescent patients, we found that acute SARS-CoV-2 infection resulted in broad immune cell reduction including T, natural killer, monocyte, and dendritic cells (DCs). DCs were significantly reduced with functional impairment, and ratios of conventional DCs to plasmacytoid DCs were increased among acute severe patients. Besides lymphocytopenia, although neutralizing antibodies were rapidly and abundantly generated in patients, there were delayed receptor binding domain (RBD)- and nucleocapsid protein (NP)-specific T cell responses during the first 3 weeks after symptoms onset. Moreover, acute RBD- and NP-specific T cell responses included relatively more CD4 T cells than CD8 T cells. Our findings provided evidence that impaired DCs, together with timely inverted strong antibody but weak CD8 T cell responses, could contribute to acute COVID-19 pathogenesis and have implications for vaccine development.


Sujets)
Betacoronavirus/pathogénicité , Lymphocytes T CD4+/immunologie , Lymphocytes T CD8+/immunologie , Infections à coronavirus/immunologie , Cellules dendritiques/immunologie , Diabète/immunologie , Hypertension artérielle/immunologie , Pneumopathie virale/immunologie , Adulte , Sujet âgé , Anticorps neutralisants/biosynthèse , Anticorps antiviraux/biosynthèse , Betacoronavirus/immunologie , Lymphocytes T CD4+/anatomopathologie , Lymphocytes T CD4+/virologie , Lymphocytes T CD8+/anatomopathologie , Lymphocytes T CD8+/virologie , COVID-19 , Convalescence , Infections à coronavirus/complications , Infections à coronavirus/diagnostic , Infections à coronavirus/virologie , Cellules dendritiques/anatomopathologie , Cellules dendritiques/virologie , Complications du diabète , Diabète/diagnostic , Diabète/virologie , Évolution de la maladie , Femelle , Humains , Hypertension artérielle/complications , Hypertension artérielle/diagnostic , Hypertension artérielle/virologie , Cellules tueuses naturelles/immunologie , Cellules tueuses naturelles/anatomopathologie , Cellules tueuses naturelles/virologie , Activation des lymphocytes , Numération des lymphocytes , Mâle , Adulte d'âge moyen , Monocytes/immunologie , Monocytes/anatomopathologie , Monocytes/virologie , Pandémies , Pneumopathie virale/complications , Pneumopathie virale/diagnostic , Pneumopathie virale/virologie , SARS-CoV-2 , Indice de gravité de la maladie
SÉLECTION CITATIONS
Détails de la recherche